Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9343(93)90095-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosis and Treatment of Polycythemia Vera: A Review.
JAMA
November 2024
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Article Synopsis
- - Polycythemia vera (PV) is a rare blood disorder affecting around 65,000 Americans, characterized by an increased mass of red blood cells, leading to a higher risk of blood clots, with symptoms such as itching and enlarged spleen.
- - Diagnosis often involves identifying elevated hemoglobin levels and the presence of a specific JAK2 gene variant, with many patients also experiencing increased platelet and white blood cell counts; survival rates range from 14 to 28 years following diagnosis.
- - Treatment typically includes therapeutic phlebotomy and low-dose aspirin for thrombosis prevention, with higher-risk patients possibly receiving additional therapies like hydroxyurea or Ruxolitinib for symptom relief; a small percentage may
Polycythemia Vera With High Serum Erythropoietin Level: A Case Report and Literature Review.
Cureus
September 2024
Internal Medicine Department, Hamad Medical Corporation, Doha, QAT.
Article Synopsis
- - Polycythemia vera (PV) is a serious blood condition characterized by an increase in red blood cells (erythrocytosis) and symptoms like headaches and weakness, often requiring the exclusion of other causes before diagnosis.
- - A case of a 47-year-old woman highlights the diagnostic process for PV, which included high hemoglobin levels and a positive JAK-2 mutation test, ultimately leading to the diagnosis despite elevated erythropoietin (EPO) levels.
- - Treatment for PV primarily involves phlebotomy to lower high blood counts, with additional options like low-dose aspirin for high-risk patients and anticoagulation for those experiencing blood clots.
Osimertinib‑induced erythromelalgia: A case report.
Exp Ther Med
July 2024
Dermatology Unit, Department of Medicine, University of Padova, I-35121 Padova, Italy.
The present study reports a case of osimertinib-induced erythromelalgia in a patient with metastatic lung adenocarcinoma. Osimertinib is an antineoplastic drug that irreversibly inhibits the epidermal growth factor receptor (EGFR) pathway by binding to the intracellular receptor tyrosine kinase site, thus preventing EGFR signal transduction. A 77-year-old female with a lung adenocarcinoma recurrence with secondary metastases was prescribed osimertinib therapy.
View Article and Find Full Text PDFArticle Synopsis
- - Erythromelalgia is a painful condition characterized by warmth, redness, and swelling in the skin, often linked to issues with blood vessel control, and has no consistently effective treatments available.
- - A 36-year-old woman was treated with interosseous membrane stimulation, receiving eight sessions over a year, which significantly alleviated her symptoms for several hours post-treatment.
- - The results suggest that interosseous membrane stimulation is a promising and safe therapy for erythromelalgia, potentially helping to correct imbalances in the autonomic nervous system affecting the extremities.
Erythromelalgia Secondary to Anti-Tumor Necrosis Factor (TNF) Alpha Therapy: A Report of Two Cases.
Cureus
February 2024
Department of Gastroenterology and Hepatology, Ibn Rochd University Hospital Center, Casablanca, MAR.
Erythromelalgia is a rare syndrome with a generally unknown etiology. Whether primary or secondary, this condition is characterized by paroxysmal episodes of erythema, pain, and heat in the extremities. We report two cases of erythromelalgia occurring after the initiation of treatment with infliximab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!